Last Price
39.00
Today's Change
+0.51 (1.32%)
Day's Change
38.29 - 39.22
Trading Volume
805,474
Market Cap
3 Billion
Shares Outstanding
76 Million
Avg Volume
632,245
Avg Price (50 Days)
34.40
Avg Price (200 Days)
31.52
PE Ratio
-6.18
EPS
-6.31
Earnings Announcement
24-Oct-2024
Previous Close
38.49
Open
38.48
Day's Range
38.29 - 39.22
Year Range
17.53 - 41.81
Trading Volume
810,642
1 Day Change
1.32%
5 Day Change
8.73%
1 Month Change
20.86%
3 Month Change
17.47%
6 Month Change
42.34%
Ytd Change
39.09%
1 Year Change
76.15%
3 Year Change
5.06%
5 Year Change
10.51%
10 Year Change
9.58%
Max Change
136.51%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.